Amarin Corp Plc (AMRN)

[couldbebetter]

CaptBeer, If Denner could convince a BP that all they would need for "success" is
to sell Vascepa to 2 million patients in Europe and 2 million patients in China at a
price of $60 a month ($720 per patient per year, "IF" economically feasible) that
would be $2.88 billion a year in revenues. Those numbers would justify a BO
of around $9 billion for AMRN or $20 a share. If a BP believed they could do such
numbers through economies of scale why wouldn't they? Especially if the drug
were ultimately priced low enough to keep out any legitimate competition.

Once pricing was determined in the world outside of the US, then the BP launches
a US branded generic, and ultimately a one-a-day version in those markets where
it would be economically feasible to do so. (My hope is that Denner has a similar
strategy in mind to entice a BP into a reasonable BO offer for AMRN.)